J Clin Neurol.  2014 Oct;10(4):281-288. 10.3988/jcn.2014.10.4.281.

Hyperhomocysteinemia and Neurologic Disorders: a Review

Affiliations
  • 1Department of Neurology, Temple University School of Medicine, Philadelphia, PA, USA. ali.mahta@tuhs.temple.edu
  • 2Department of Pediatrics, Weill Cornell Medical Center-New York Presbyterian Hospital, New York, NY, USA.

Abstract

Homocysteine (Hcy) is a sulfur-containing amino acid that is generated during methionine metabolism. It has a physiologic role in DNA metabolism via methylation, a process governed by the presentation of folate, and vitamins B6 and B12. Physiologic Hcy levels are determined primarily by dietary intake and vitamin status. Elevated plasma levels of Hcy (eHcy) can be caused by deficiency of either vitamin B12 or folate, or a combination thereof. Certain genetic factors also cause eHcy, such as C667T substitution of the gene encoding methylenetetrahydrofolate reductase. eHcy has been observed in several medical conditions, such as cardiovascular disorders, atherosclerosis, myocardial infarction, stroke, minimal cognitive impairment, dementia, Parkinson's disease, multiple sclerosis, epilepsy, and eclampsia. There is evidence from laboratory and clinical studies that Hcy, and especially eHcy, exerts direct toxic effects on both the vascular and nervous systems. This article provides a review of the current literature on the possible roles of eHcy relevant to various neurologic disorders.

Keyword

hyperhomocysteinemia; neurologic disorders; pregnancy

MeSH Terms

Atherosclerosis
Dementia
DNA
Eclampsia
Epilepsy
Female
Folic Acid
Homocysteine
Hyperhomocysteinemia*
Metabolism
Methionine
Methylation
Methylenetetrahydrofolate Reductase (NADPH2)
Multiple Sclerosis
Myocardial Infarction
Nervous System
Nervous System Diseases*
Parkinson Disease
Plasma
Pregnancy
Stroke
Vitamin B 12
Vitamins
DNA
Folic Acid
Homocysteine
Methionine
Methylenetetrahydrofolate Reductase (NADPH2)
Vitamin B 12
Vitamins

Cited by  1 articles

The Effect of Vitamin B12 and Folic Acid Supplementation on Serum Homocysteine, Anemia Status and Quality of Life of Patients with Multiple Sclerosis
Ehsan Nozari, Saied Ghavamzadeh, Nazanin Razazian
Clin Nutr Res. 2019;8(1):36-45.    doi: 10.7762/cnr.2019.8.1.36.


Reference

1. Maxwell SR. Coronary artery disease--free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol. 2000; 95:Suppl 1. I65–I71.
2. Graham IM, O'Callaghan P. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther. 2002; 16:383–389.
3. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998; 157:Suppl 2. S40–S44.
Article
4. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999; 19:217–246.
Article
5. Pietrzik K, Brönstrup A. Vitamins B12, B6 and folate as determinants of homocysteine concentration in the healthy population. Eur J Pediatr. 1998; 157:Suppl 2. S135–S138.
Article
6. Huang YC, Chang SJ, Chiu YT, Chang HH, Cheng CH. The status of plasma homocysteine and related B-vitamins in healthy young vegetarians and nonvegetarians. Eur J Nutr. 2003; 42:84–90.
Article
7. Kulkarni K, Richard BC. Lifestyle, homocysteine, and the metabolic syndrome. Metab Syndr Relat Disord. 2003; 1:141–147.
Article
8. Stea TH, Mansoor MA, Wandel M, Uglem S, Frølich W. Changes in predictors and status of homocysteine in young male adults after a dietary intervention with vegetables, fruits and bread. Eur J Nutr. 2008; 47:201–209.
Article
9. Di Santolo M, Banfi G, Stel G, Cauci S. Association of recreational physical activity with homocysteine, folate and lipid markers in young women. Eur J Appl Physiol. 2009; 105:111–118.
Article
10. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006; 354:2764–2772.
Article
11. Katko M, Kiss I, Karpati I, Kadar A, Matyus J, Csongradi E, et al. Relationship between serum nickel and homocysteine concentration in hemodialysis patients. Biol Trace Elem Res. 2008; 124:195–205.
Article
12. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Homocysteine: an emerging cardiovascular risk factor that never really made it. Open Clin Chem J. 2010; 3:19–24.
Article
13. Heinecke JW. Biochemical evidence for a link between elevated levels of homocysteine and lipid peroxidation in vivo. Curr Atheroscler Rep. 1999; 1:87–89.
Article
14. Misra UK, Kalita J, Srivastava AK, Agarwal S. MTHFR gene polymorphism and its relationship with plasma homocysteine and folate in a North Indian population. Biochem Genet. 2010; 48:229–235.
Article
15. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288:2023–2031.
Article
16. Brattström L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998; 98:2520–2526.
Article
17. Fux R, Kloor D, Hermes M, Röck T, Proksch B, Grenz A, et al. Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. Am J Physiol Renal Physiol. 2005; 289:F786–F792.
Article
18. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci. 2009; 338:48–49.
19. Pexa A, Fischer K, Deussen A, Henle T. Homocysteine in food. Eur Food Res Technol. 2008; 226:933–935.
Article
20. Frank J, Beck SC, Flaccus A, Biesalski HK. No evidence for prooxidative effects of homocysteine in vascular endothelial cells. Eur J Nutr. 2007; 46:286–292.
Article
21. Kelly PJ, Furie KL. Management and Prevention of Stroke Associated with Elevated Homocysteine. Curr Treat Options Cardiovasc Med. 2002; 4:363–371.
Article
22. Selhub J, D'Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci. 1998; 316:129–141.
Article
23. Tacconelli S, Capone ML, Patrignani P. Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation. Methods Mol Biol. 2010; 644:165–178.
24. Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 1999; 83:1287–1290.
Article
25. Lim MH, Cho YI, Jeong SK. Homocysteine and pulsatility index of cerebral arteries. Stroke. 2009; 40:3216–3220.
Article
26. Sen S, Reddy PL, Grewal RP, Busby M, Chang P, Hinderliter A. Hyperhomocysteinemia is Associated with Aortic Atheroma Progression in Stroke/TIA Patients. Front Neurol. 2010; 1:131.
Article
27. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008; 29:1–11.
Article
28. Moustafa AA, Hewedi DH, Eissa AM, Myers CE, Sadek HA. The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One. 2012; 7:e46496.
Article
29. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010; 5:e12244.
Article
30. Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, et al. Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis. 2011; 27:909–922.
Article
31. Blasko I, Hinterberger M, Kemmler G, Jungwirth S, Krampla W, Leitha T, et al. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging. 2012; 16:687–694.
Article
32. Kim G, Kim H, Kim KN, Son JI, Kim SY, Tamura T, et al. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J Alzheimers Dis. 2013; 33:853–862.
Article
33. Reitz C, Tang MX, Miller J, Green R, Luchsinger JA. Plasma homocysteine and risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2009; 27:11–17.
Article
34. Annerbo S, Wahlund LO, Lökk J. The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer's disease in mild cognitive impairment: a 6-year follow-up study. Am J Alzheimers Dis Other Demen. 2006; 21:182–188.
Article
35. Postiglione A, Milan G, Ruocco A, Gallotta G, Guiotto G, Di Minno G. Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study. Gerontology. 2001; 47:324–329.
Article
36. Tyagi SC, Lominadze D, Roberts AM. Homocysteine in microvascular endothelial cell barrier permeability. Cell Biochem Biophys. 2005; 43:37–44.
Article
37. Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med. 2005; 118:161–167.
Article
38. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, et al. Vitamins B(12), B(6), and folic acid for cognition in older men. Neurology. 2010; 75:1540–1547.
Article
39. Nilsson K, Gustafson L, Hultberg B. Elevated plasma homocysteine level is not primarily related to Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34:121–127.
Article
40. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord. 2013; 28:14–23.
Article
41. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol. 2012; 2012:845618.
Article
42. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord. 2012; 27:947–957.
Article
43. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. 2012; 27:1276–1282.
Article
44. Luo JJ, Dun NJ. Estrogen and Parkinson's disease. Curr Trends Neurol. 2011; 5:49–57.
45. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014; 11:6–23.
Article
46. Białecka M, Robowski P, Honczarenko K, Roszmann A, Sławek J. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. Neurol Neurochir Pol. 2009; 43:272–285.
47. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80:101–110.
Article
48. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003; 26:137–146.
Article
49. Doherty GH. Homocysteine and Parkinson's disease: a complex relationship. J Neurol Disord. 2013; 1:107.
Article
50. Brosnan JT, Jacobs RL, Stead LM, Brosnan ME. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol. 2004; 51:405–413.
Article
51. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005; 11:131–133.
Article
52. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997; 20:55–66.
Article
53. Müller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999; 354:126–127.
Article
54. Müller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol. 2006; 62:447–450.
Article
55. Hu XW, Qin SM, Li D, Hu LF, Liu CF. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol Scand. 2013; 128:73–82.
Article
56. Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment? Curr Med Chem. 2010; 17:213–221.
Article
57. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F. Homocysteine and Parkinson's disease: a dangerous liaison? J Neurol Sci. 2007; 257:31–37.
Article
58. Sahin S, Aksungar FB, Topkaya AE, Yildiz Z, Boru UT, Ayalp S, et al. Increased plasma homocysteine levels in multiple sclerosis. Mult Scler. 2007; 13:945–946.
Article
59. Ramsaransing GS, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De Keyser J. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006; 77:189–192.
Article
60. Vrethem M, Mattsson E, Hebelka H, Leerbeck K, Osterberg A, Landtblom AM, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler. 2003; 9:239–245.
Article
61. Río J, Montalban J, Tintoré M, Codina A, Malinow MR. Serum homocysteine levels in multiple sclerosis. Arch Neurol. 1994; 51:1181.
Article
62. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002; 70:694–702.
Article
63. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000; 20:6920–6926.
Article
64. Kararizou E, Paraskevas G, Triantafyllou N, Koutsis G, Evangelopoulos ME, Mandellos D, et al. Plasma homocysteine levels in patients with multiple sclerosis in the Greek population. J Chin Med Assoc. 2013; 76:611–614.
Article
65. Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008; 79:1349–1353.
Article
66. Russo C, Morabito F, Luise F, Piromalli A, Battaglia L, Vinci A, et al. Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol. 2008; 255:64–69.
Article
67. Smith DE, Hornstra JM, Kok RM, Blom HJ, Smulders YM. Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism. Clin Chem Lab Med. 2013; 51:1643–1650.
Article
68. Walker MC, Smith GN, Perkins SL, Keely EJ, Garner PR. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol. 1999; 180(3 Pt 1):660–664.
Article
69. Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003; 17:459–469.
Article
70. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000; 71:962–968.
Article
71. Patel AP, Chakrabarti C, Singh A, Pate JD, Mewada HA, Sharma SL. Effect of Homocysteine, Vitamin B12, Folic acid during pregnancy. NHL J Med Sci. 2012; 1:27–31.
72. National Institute of Child Health and Human Development (US) [Internet]. How many people are affected by or are at risk for neural tube defects? Bethesda, MD: National Institute of Child Health and Human Development;updated 2012 Nov 30. cited 2014 Jul. Available from: https://www.nichd.nih.gov/health/topics/ntds/conditioninfo/Pages/risk.aspx.
73. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Najjar MF. Effect of cigarette smoking on plasma homocysteine concentrations. Clin Chem Lab Med. 2011; 49:479–483.
74. Coker I, Colak A, Gunaslan Hasturk A, Yildiz O, Turkon H, Halicioglu O. Maternal and cord blood homocysteine and folic acid levels in smoking and nonsmoking pregnant women. Gynecol Obstet Invest. 2011; 71:245–249.
Article
75. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991; 338:131–137.
76. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992; 327:1832–1835.
Article
77. Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, Blom HJ, Eskes TK. Congenital heart defects and maternal derangement of homocysteine metabolism. J Pediatr. 1999; 135:773–774.
Article
78. Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, Nassar BA, et al. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem. 2008; 54:326–334.
Article
79. Khosrowbeygi A, Ahmadvand H. Circulating levels of homocysteine in preeclamptic women. Bangladesh Med Res Counc Bull. 2011; 37:106–109.
Article
80. Harma M, Harma M, Kocyigit A. Correlation between maternal plasma homocysteine and zinc levels in preeclamptic women. Biol Trace Elem Res. 2005; 104:97–105.
Article
81. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995; 346:1070–1071.
Article
82. Hobbs CA, James SJ, Jernigan S, Melnyk S, Lu Y, Malik S, et al. Congenital heart defects, maternal homocysteine, smoking, and the 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene: evaluating gene-environment interactions. Am J Obstet Gynecol. 2006; 194:218–224.
Article
83. He X, Hong X, Zeng F, Kang F, Li L, Sun Q. Zinc antagonizes homocysteine-induced fetal heart defects in rats. Cardiovasc Toxicol. 2009; 9:151–159.
Article
84. Belcastro V, Striano P, Gorgone G, Costa C, Ciampa C, Caccamo D, et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010; 51:274–279.
Article
85. Belcastro V, Gaetano G, Italiano D, Oteri G, Caccamo D, Pisani LR, et al. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia. 2007; 48:1990–1994.
Article
86. Chango A, Boisson F, Barbé F, Quilliot D, Droesch S, Pfister M, et al. The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr. 2000; 83:593–596.
Article
87. Gorgone G, Caccamo D, Pisani LR, Currò M, Parisi G, Oteri G, et al. Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia. 2009; 50:Suppl 1. 33–36.
Article
88. Flott-Rahmel B, Schürmann M, Schluff P, Fingerhut R, Musshoff U, Fowler B, et al. Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur J Pediatr. 1998; 157:Suppl 2. S112–S117.
Article
89. Bruce SG, Young TK. Prevalence and risk factors for neuropathy in a Canadian First Nation community. Diabetes Care. 2008; 31:1837–1841.
Article
90. Ambrosch A, Dierkes J, Lobmann R, Kühne W, König W, Luley C, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med. 2001; 18:185–192.
Article
91. Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci. 2001; 87:268–273.
Article
92. González R, Pedro T, Martinez-Hervas S, Civera M, Priego MA, Catalá M, et al. Plasma homocysteine levels are independently associated with the severity of peripheral polyneuropathy in type 2 diabetic subjects. J Peripher Nerv Syst. 2012; 17:191–196.
Article
93. Jianbo L, Yuche C, Ming S, Jingrong T, Qing D, Yu Z, et al. Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract. 2011; 93:38–42.
Article
94. Luo JJ, Sivaraaman K, Nouh A, Dun NJ. Elevated plasma level of homocysteine is an independent risk factor for peripheral neuropathy. British J Med Med Res. 2014; 4:161–169.
Article
95. Weir DG, Keating S, Molloy A, McPartlin J, Kennedy S, Blanchflower J, et al. Methylation deficiency causes vitamin B12-associated neuropathy in the pig. J Neurochem. 1988; 51:1949–1952.
Article
96. Cullen CE, Carter GT, Weiss MD, Grant PA, Saperstein DS. Hypohomocysteinemia: a potentially treatable cause of peripheral neuropathology? Phys Med Rehabil Clin N Am. 2012; 23:59–65. x
Article
97. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013; 19:501–507. discussion 501.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr